nach oben

Erschienen in:

01.09.2014 | Research Article

The diplotype Fas −1377A/−670G as a genetic marker to predict a lower risk of breast cancer in Chinese women

verfasst von: Yeqiong Xu, Qiwen Deng, Bangshun He, Yuqin Pan, Rui Li, Tianyi Gao, Huiling Sun, Guoqi Song, Shukui Wang, William C. Cho

Erschienen in: Tumor Biology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

This study was designed to reveal the effects of Fas and FasL polymorphisms of interest on breast cancer risk. A total of 439 patients with breast cancer and 439 controls were enrolled in this study. The genotypes Fas −1377G/A, Fas −670A/G, and FasL −844 T/C were detected by MassARRAY. The protein expressions of estrogen receptor, progesterone receptor, and CerbB-2 were determined by immunohistochemistry. Among the 439 patients, Fas mRNA levels in 22 samples of breast cancer and adjacent normal tissues were detected by real-time polymerase chain reaction, and the soluble Fas and Fas ligand concentrations of 180 patients were measured by enzyme-linked immunosorbent assay. The Fas −1377GA, Fas −1377AA, Fas −670AG, Fas −670GG, and FasL −844TC genotypes were associated with a reduced risk of breast cancer. Haplotype analysis indicated that Fas −1377G/−670A was associated with an increased risk of breast cancer, whereas Fas −1377A/−670A was associated with the opposite effect. Furthermore, gene–gene interaction analysis revealed that the Fas −1377GA/AA (−670AG/GG) and FasL −844CC or TC/TT genotypes were associated with a decreased risk of breast cancer. Meanwhile, −1377GG and −670AA genotypes were associated with higher soluble Fas concentrations than other genotypes. We conclude that Fas and FasL polymorphisms can affect breast cancer risk and that Fas polymorphisms are likely to affect breast cancer risk by regulating the soluble Fas concentration.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

Wang W, Zheng Z, Yu W, Lin H, Cui B, Cao F. Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett. 2012;3(3):625–8. doi:10.3892/ol.2011.541.PubMedCentralPubMed

Fan XQ, Guo YJ. Apoptosis in oncology. Cell Res. 2001;11(1):1–7. doi:10.1038/sj.cr.7290060.PubMedCrossRef

Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485–95.PubMedCrossRef

Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–8. doi:10.1038/35077213.PubMedCrossRef

Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18(5):240–4.PubMedCrossRef

Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305–8.PubMedCrossRef

Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol. 2004;4(4):321–6. doi:10.1016/j.coph.2004.03.008.PubMedCrossRef

Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med (Berl). 2000;78(6):312–25.CrossRef

10.

Zhang B, Sun T, Xue L, Han X, Lu N, Shi Y, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis. 2007;28(5):1067–73. doi:10.1093/carcin/bgl250.PubMedCrossRef

11.

Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis. 2007;28(12):2548–51. doi:10.1093/carcin/bgm211.PubMedCrossRef

12.

Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One. 2013;8(1):e53075. doi:10.1371/journal.pone.0053075.PubMedCentralPubMedCrossRef

13.

Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol. 2012;73(9):932–8. doi:10.1016/j.humimm.2012.06.001.PubMedCrossRef

14.

Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96(19):1478–9. doi:10.1093/jnci/djh289. author reply 9.PubMedCrossRef

15.

Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263(5154):1759–62.PubMedCrossRef

16.

Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154(6):2706–13.PubMed

17.

Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol. 1996;156(12):4622–30.PubMed

18.

Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999;5(11):3529–33.PubMed

19.

Sheen-Chen SM, Chen HS, Eng HL, Chen WJ. Circulating soluble Fas in patients with breast cancer. World J Surg. 2003;27(1):10–3. doi:10.1007/s00268-002-6378-5.PubMedCrossRef

20.

Gregory MS, Saff RR, Marshak-Rothstein A, Ksander BR. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand. Cancer Res. 2007;67(24):11951–8. doi:10.1158/0008-5472.CAN-07-0780.PubMedCrossRef

21.

Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009;Chapter 2:Unit 2 12. doi:10.1002/0471142905.hg0212s60.

22.

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347–51. doi:10.1038/ng1975.PubMedCrossRef

23.

Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, Sensu S, et al. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol. 2010;5:13. doi:10.1186/1746-1596-5-13.PubMedCentralPubMedCrossRef

24.

Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 2000;320(7247):1468.PubMedCentralPubMedCrossRef

25.

Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer. 2004;100(11):2281–91. doi:10.1002/cncr.20270.PubMedCrossRef

26.

Shao P, Ding Q, Qin C, Wang M, Tang J, Zhu J, et al. Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate. 2011;71(10):1122–30. doi:10.1002/pros.21328.PubMedCrossRef

27.

Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006;16(4):253–63. doi:10.1097/01.fpc.0000199501.54466.de.PubMedCrossRef

28.

Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34(8–9):577–82.PubMedCrossRef

29.

Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327–30.PubMed

30.

Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol. 2009;182(6):3801–8. doi:10.4049/jimmunol.0801548.PubMedCrossRef

31.

Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–99.PubMedCrossRef

32.

Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175(7):4583–92.PubMedCentralPubMedCrossRef

33.

Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood. 2007;109(10):4336–42. doi:10.1182/blood-2006-09-046201.PubMedCentralPubMedCrossRef

34.

Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis. 2003;8(2):151–60.PubMedCrossRef

35.

Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res. 2006;12(12):3705–12. doi:10.1158/1078-0432.CCR-05-2493.PubMedCrossRef

36.

Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994;54(6):1580–6.PubMed

37.

Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res. 2000;60(6):1766–72.PubMed

38.

Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004;23(15):3175–85. doi:10.1038/sj.emboj.7600325.PubMedCentralPubMedCrossRef

39.

Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, et al. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol. 1999;188(2):207–12. doi:10.1002/(SICI)1096-9896(199906)188:2<207::AID-PATH337>3.0.CO;2-8.PubMedCrossRef

40.

Furuya Y, Fuse H, Masai M. Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res. 2001;21(5):3595–8.PubMed

41.

Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, et al. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer. 2002;95(2):296–300. doi:10.1002/cncr.10674.PubMedCrossRef

42.

Furuya Y, Nagakawa O, Fuse H. Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer. Endocr J. 2003;50(5):629–33.PubMedCrossRef

43.

Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–8.PubMedCrossRef

44.

Wiechec E, Hansen LL. The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol. 2009;625(1–3):122–30. doi:10.1016/j.ejphar.2009.08.045.PubMedCrossRef

45.

Wiechec E. Implications of genomic instability in the diagnosis and treatment of breast cancer. Expert Rev Mol Diagn. 2011;11(4):445–53. doi:10.1586/erm.11.21.PubMedCrossRef

46.

Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri AM. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys. 2010;500(2):116–22. doi:10.1016/j.abb.2010.05.012.PubMedCrossRef

47.

48.

Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, et al. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010;28(5):554–9. doi:10.3109/07357900903286925.PubMedCrossRef

49.

Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat. 2008;111(1):93–101. doi:10.1007/s10549-007-9764-8.PubMedCrossRef

50.

Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer. 2005;103(1):52–8. doi:10.1002/cncr.20729.PubMedCrossRef

51.

Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(3):437–46. doi:10.1007/s00280-009-1046-1.PubMedCentralPubMedCrossRef

52.

Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, et al. Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer. 2008;98(12):2006–10. doi:10.1038/sj.bjc.6604394.PubMedCentralPubMedCrossRef

53.

54.

Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003;22(5):1117–21.PubMed

Titel: The diplotype Fas −1377A/−670G as a genetic marker to predict a lower risk of breast cancer in Chinese women
verfasst von: Yeqiong Xu
Qiwen Deng
Bangshun He
Yuqin Pan
Rui Li
Tianyi Gao
Huiling Sun
Guoqi Song
Shukui Wang
William C. Cho
Publikationsdatum: 01.09.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 9/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2175-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

The diplotype Fas −1377A/−670G as a genetic marker to predict a lower risk of breast cancer in Chinese women

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies

Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer

Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma

Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy

Relevance of miR-21 in HIV and non-HIV-related lymphomas

Expression of MLH1 and MSH2 in urothelial carcinoma of the renal pelvis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie